EZH2甲基转移酶通过表观遗传调控染色体不稳定性
该研究揭示EZH2组蛋白甲基转移酶在三阴性乳腺癌中直接促进染色体不稳定性(CIN),EZH2表达与拷贝数改变相关,其催化活性与转移起始细胞的CIN增加相关。药理学抑制EZH2可抑制CIN,机制上EZH2转录抑制TNKS,进而破坏CPAP,驱动中心体过度复制和多极有丝分裂。体内实验表明CIN抑制是EZH2抑制剂抗转移作用的关键机制。
要点
- EZH2表达与乳腺癌拷贝数改变相关,其催化活性与转移起始细胞CIN增加相关。
- EZH2通过转录抑制TNKS、破坏CPAP,驱动中心体过度复制和多极有丝分裂。
- EZH2抑制剂是首个能直接抑制CIN的治疗药物,CIN抑制是其抗转移关键机制。
核心结论
- EZH2通过EZH2-TNKS-CPAP轴表观遗传调控CIN,CIN抑制是EZH2抑制剂抗转移疗效的重要机制。
研究设计与样本
- 研究在三阴性乳腺癌中开展,整合染色质与转录组分析,并在体内验证EZH2抑制的抗转移作用。
主要发现
- EZH2表达与乳腺癌拷贝数改变相关,其催化活性与转移起始细胞CIN增加相关。
- 药理学抑制EZH2可抑制CIN,揭示意外脆弱性。
- EZH2介导的TNKS抑制破坏CPAP,驱动中心体过度复制、多极有丝分裂和加剧的CIN。
- 体内CIN抑制是EZH2抑制剂抗转移效果的关键机制。
临床怎么用
- EZH2抑制剂作为首个直接抑制CIN的治疗药物,提示需开展以转移为重点终点的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. Here, we uncover a direct role for EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer. Across breast cancers, EZH2 expression correlates with copy-number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacologic EZH2 inhibition suppresses CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified tankyrase (TNKS), a PARP, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts centrosomal P4.1-associated protein (CPAP), driving centrosome overduplication, multipolar mitosis, and exacerbated CIN. In vivo, CIN suppression is a critical mechanism underlying the antimetastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints. SIGNIFICANCE: We elucidate epigenetic regulation of CIN through EZH2-TNKS-CPAP-axis and show that CIN suppression is important for the efficacy of EZH2 inhibition on metastasis. These mechanistic insights are informative for developing CIN-suppressing therapies.
引用
- Bai Y, Agustinus AS, Yomtoubian S, et al. Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer Discov. 2026. PMID: 41036949. doi:10.1158/2159-8290.CD-25-0947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。